CN108478553A - Based on the inflammatory conditions protective agents of blood vessel endothelium inflammatory damage and its application - Google Patents
Based on the inflammatory conditions protective agents of blood vessel endothelium inflammatory damage and its application Download PDFInfo
- Publication number
- CN108478553A CN108478553A CN201810330838.5A CN201810330838A CN108478553A CN 108478553 A CN108478553 A CN 108478553A CN 201810330838 A CN201810330838 A CN 201810330838A CN 108478553 A CN108478553 A CN 108478553A
- Authority
- CN
- China
- Prior art keywords
- inflammatory
- group
- cga
- res
- chlorogenic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Inflammatory conditions protective agents based on blood vessel endothelium inflammatory damage, the drug are the mixture of chlorogenic acid and resveratrol, application of the drug in terms of vascular inflammatory illness.The drug can the induction of substantially reduced complement bypass-activation chmice acute injury of lungs, mechanism may be with the phosphorylation for inhibiting NF κ B p65 and to reduce inflammatory reaction degree related.
Description
Technical field
The present invention relates to the inflammatory conditions prevention and control fields of blood vessel endothelium inflammatory damage, more particularly to are based on intravascular dermatitis
Property damage inflammatory conditions protective agents and its application.
Background technology
Acute lung injury (acute lung injury, ALI) be endanger human health a kind of common clinical it is suddenly critical
Disease, case fatality rate is high, seriously threatens the life of patient and influences its life quality, clinically also lacks having for treatment ALI at present
Effect means.ALI morbidity early stages, complement system are activated first, especially the inflammation of microvascular endothelial cells caused by complement activation
Disease is reacted and damage plays key player in the occurrence and development of ALI.
Chlorogenic acid, (Chlorogenic acid, CGA) belong to polyphenol compound, are primarily present in honeysuckle, mountain silver
In many medicinal materials such as flower, Cortex Eucommiae and food materials, there are the multiple biological activities such as anti-inflammatory, anti-oxidant.Resveratrol (resveratrol,
Res it is) a kind of polyphenol compound, is primarily present in the plants such as grape, peanut and giant knotweed that there is anti-oxidant, anticancer, anti-inflammatory
The effects that.Our early-stage studies find that CGA and Res has human microvascular endothelial cell (mvec) inflammatory reaction caused by complement bypass-activation
There is preferable intervention effect, and the two combination has better intervention effect.Therefore, this experiment is caused using complement bypass-activation
ALI mouse models the protective effect of CGA+Res is studied and is evaluated.
Invention content
To solve the above-mentioned problems of the prior art, the purpose of the present invention is to provide based on blood vessel endothelium inflammatory damage
Inflammatory conditions protective agents and its application；
In order to achieve the above objectives, the technical scheme is that：
Inflammatory conditions protective agents based on blood vessel endothelium inflammatory damage, the drug are chlorogenic acid and resveratrol
Mixture.
Further, the proportioning of the mixture is 4-6 parts of chlorogenic acid by weight, 1-3 parts of resveratrol.
Further, the proportioning of the mixture is 5 parts of chlorogenic acid by weight, 5 parts of resveratrol.
Further, the mixture is pill, tablet, injection or capsule.
Further, the application of the inflammatory conditions protective agents based on blood vessel endothelium inflammatory damage, specially：It should
Application of the drug in terms of acute lung injury.
Compared with the existing technology, beneficial effects of the present invention are：
Chlorogenic acid is medicine common drug, but is not intended as before medically only using chlorogenic acid as detection indicator
Specific medicinal ingredient thinks that it does not occur curative effect, the present invention it has been investigated that, the mixing of chlorogenic acid and resveratrol
Object has the function of curing the inflammatory conditions based on blood vessel endothelium inflammatory damage well, effect better than be applied alone chlorogenic acid or
Resveratrol, and dosage significantly reduces, and has broken existing technology prejudice, has been of great significance.
Description of the drawings
Fig. 1 is resveratrol and chlorogenic acid drug combination to inflammatory mediator and adhesion molecule in mice with acute lung injury BALF
Influence (n=8, M ± SD)；Wherein, Figure 1A (A：The concentration of IL-6 in mouse BALF；B：The concentration of TNF- in mouse BALF)；
Figure 1B (C：The concentration of P-selectin in mouse BALF；B：The concentration of ICAM-1 in mouse BALF)；
Fig. 2 resveratrols and chlorogenic acid drug combination are to inflammatory mediator in mice with acute lung injury serum and adhesion molecule
It influences (n=8, M ± SD)；Wherein, Fig. 2A (A：The concentration of IL-6 in mice serum；B：The concentration of TNF- in mice serum)；Figure
2B(C：The concentration of P-selectin in mice serum；D：The concentration of ICAM-1 in mice serum)
Fig. 3 mouse lung tissues pathologic examination (× 200)；Wherein, A：Normal group；B：Model group；C：Resveratrol
Group；D：Chlorogenic acid group；E resveratrols and chlorogenic acid drug combination group
Fig. 4 is chlorogenic acid and resveratrol combination to NF- κ B p65 phosphorylation levels in mice with acute lung injury lung tissue
Influence diagram (× 200) (n=8, M ± SD), Fig. 4 A be lung tissue immunohistochemistry testing result (× 200)
(A：Normal group；B：Model group；C：Resveratrol group；D：Chlorogenic acid group；E resveratrols and chlorogenic acid drug combination
Group)；Fig. 4 B are the analysis of NF- κ B p65 phosphorylation levels in lung tissue, wherein A：Normal group；B：Model group；C：Resveratrol
Group；D：Chlorogenic acid group；E：Resveratrol and chlorogenic acid drug combination group
Note：Compared with normal group, #P<0.05, ##P<0.01；Compared with model group, * P<0.05, * * P<0.01；With white lamb's-quarters
Reed alcohol+chlorogenic acid group compares,ΔP<0.05,ΔΔP<0.01。
Specific implementation mode
Technical solution of the present invention is described in further detail with reference to the accompanying drawings and detailed description：
As shown in Figure 1, experimental example：
Acute lung injury (acute lung injury, ALI) be endanger human health a kind of common clinical it is suddenly critical
Disease, case fatality rate is high, seriously threatens the life of patient and influences its life quality, clinically also lacks having for treatment ALI at present
Effect means.ALI morbidity early stages, complement system are activated first, especially the inflammation of microvascular endothelial cells caused by complement activation
Disease is reacted and damage plays key player in the occurrence and development of ALI.Chlorogenic acid (chlorogenic acid, CGA) is gold
Typical reactive ingredient in many medicinal materials such as honeysuckle flower, Honeysuckle flower, Cortex Eucommiae has the effects that antibacterial, antiviral, anti-inflammatory.White black false hellebore
Alcohol (resveratrol, Res) is a kind of polyphenol compound, is primarily present in the plants such as grape, peanut and giant knotweed, has
Anti-oxidant, anticancer, it is anti-inflammatory the effects that.Our early-stage studies find CGA and Res in people's capilary caused by complement bypass-activation
Chrotoplast inflammatory reaction has preferable intervention effect, and the two combination has better intervention effect.Therefore, this experiment uses
ALI mouse models caused by complement bypass-activation are studied and are evaluated to the protective effect of CGA+Res.
1, experiment material
KM mouse, half male and half female are purchased from Hunan SJA Laboratory Animal Co. , Ltd, production licence：SCXK-
(Hunan) -2013-0004.Cobra-venom factor (cobra venom factor, CVF) is that this project team system is standby.Chlorogenic acid
(CGA), resveratrol (resveratrol, Res) is purchased from Beijing Suo Laibao Co., Ltds.MPO kits build up life purchased from Nanjing
Object Graduate School of Engineering.Mouse IL-6, TNF-α, P-selectin, ICAM-1ELISA kit are purchased from Wuhan doctor's moral biology work
Journey Co., Ltd.NF- κ B p65 antibody is purchased from Santa Cruz companies.Two sulphur amino first of nuclear factor NF- kB inhibitors pyrrolidines
Sour (PDTC), BCA protein quantification kits are purchased from the green skies biotechnology research institute in Jiangsu.All operations and experiment flow are equal
It abides by《Management of laboratory animal regulations》.Experimental situation：Constant temperature (22 ± 2) DEG C, humidity 60%~70%, free water and feed.
2, experimental method
2.1 modellings and administration materials
SPF grades of KM mouse (25 ± 3g) 32 after adaptable fed 5d, are randomly divided into Normal group, model after weighing
Group, Res 40mg/kg groups, CGA 100mg/kg groups, Res+CGA groups (20mg Res+50mg CGA)/kg groups, every group 8.Res
It is dissolved in 0.2%CMCNa, continuous gavage prevention administration 7d respectively with CGA, one time a day, Normal group and model group give equal bodies
Product 0.2%CMCNa.The CVF (with the PBS dilutions that sterilize) of 25 μ g/kg of 1h tail vein injections, Normal group tail after 7d administrations
It is injected intravenously isometric PBS.Each group mouse prevention administration 7d, in 7d administration after 25 μ g/kg of 1h tail vein injections CVF (with
Sterilize PBS dilutions), the isometric PBS of Normal group tail vein injection.Give 1h after CVF and pluck eyeball and take blood, 3000r/min from
Heart 10min prepares serum；Then mouse is put to death, thoracic cavity is opened and gently provokes right lung, right lung, exposure tracheae, row are clamped with artery clamp
Trachea cannula, left lung carry out bronchoalveolar lavage with 4 DEG C of 1.2mL physiology salt moisture 4 times, each 0.3mL, back and forth lavation 3
It is secondary, BAL fluid (BALF) row cell count is obtained, 4 DEG C of BALF 3000r/min centrifuge 10min after counting, take supernatant
Liquid dispense, -80 DEG C freeze it is spare.Superior lobe of right lung is placed in -80 DEG C to freeze, the middle lobe of right lung claims weight in wet base, inferior lobe of right lung to be placed in more than 4%
It is fixed in polyformaldehyde solution.
2.2 moisture content of lung and MPO are measured
Mouse modeling is drawn materials after weighing, and superior lobe of right lung freezes at once in -80 DEG C after taking out and measured for MPO, specific method
It is carried out according to kit specification.Middle lobe of right lung claims weight in wet base, then with 70 DEG C of baking 48h to constant weight, according to formula：(weight in wet base-is dry
Weight)/weight in wet base × 100%, calculate moisture content of lung.
2.3BALF cell counts and determination of protein concentration
Take BALF liquid, row cell count, the total number of cells n of five big lattice on count plate, by formula：Cell number (a/
ML)=total number of cells n/80 × 400 × 104.BALF supernatants are taken, are detected using BCA methods, is measured and is inhaled in 562nm with microplate reader
Shading value simultaneously calculates albumen concentration in BALF.
The measurement of 2.4 inflammatory mediators and adhesion molecule
BALF supernatants and serum are taken, ELISA method detection is used according to kit specification, is surveyed in 450nm with microplate reader
Determine absorbance value and calculates the content of IL-6, TNF-α, P-selectin and ICAM-1.
2.5 pathologic inspections and immunohistochemistry measure
After lavation, inferior lobe of right lung is taken to be fixed with 4% paraformaldehyde solution, makes routine paraffin wax pathological section, HE dyes
Color, microscopically observation.And make immunohistochemical staining, it is positive anti-to occur brown color or brown particle in karyon or endochylema
It answers, with 5.0 image analyses of IPP, measures Positive area and OD value, calculate average optical density value and counted
Analysis, detection NF- κ B p65 Expression of phosphorylated are horizontal.
2.6 statistical analysis
Experimental result is indicated with means standard deviation (M ± SD), for statistical analysis with SPSS 18.0, using t examine into
Row statistical analysis.The data of Non-Gaussian Distribution compare using nonparametric statistical method.P<0.05 is statistically significant for difference.
3 experimental results
Influences of the 3.1Res+CGA to ALI mouse lung tissue indexs of correlation
Compared with normal group, model group mouse BALF cell numbers and MPO contents significantly increase (P<0.05,0.01).With
Model group compares, and Res, CGA, Res+CGA can substantially reduce BALF cell numbers (P<0.05,0.01) MPO contents (P, is reduced
<0.01).The BALF cell numbers of Res+CGA groups are significantly lower than Res groups and CGA groups (P<0.05) model group protein content is higher than
Normal group, Res+CGA can significantly reduce protein content (P in mouse BALF after prevention administration<0.05), Res, CGA also may be used
Reduce protein content in mouse BALF, but no significant difference (P>0.05).Each group mouse moisture content of lung becomes without apparent after administration
Change (P>0.05), it is shown in Table 1.
Influence (the n of 1 resveratrol of table and chlorogenic acid drug combination to acute lung injury model mouse lung tissue index of correlation
=8, M ± SD)
1 Effects of Res+CGA on related lung items of ALI mice of Table (n=8, M ±
SD)
Note：Compared with normal group,#P<0.05,##P<0.01；Compared with model group,*P<0.05,**P<0.01；With white black false hellebore
Alcohol+chlorogenic acid group compares, Δ P<0.05, Δ Δ P<0.013.2Res+CGA to inflammatory mediator in ALI mouse BALF and stick point
The influence of son
Res+CGA groups can make inflammatory mediator IL-6 in mouse BALF, TNF-α and adhesion molecule P-selectin, ICAM-
1 content reduces, with the statistically significant (P of model group comparing difference<0.05,0.01).Res, CGA can be significantly reduced simultaneously
IL-6, TNF-α content, Res can also reduce P-selectin contents in BALF in BALF, have statistics with model group comparing difference
Meaning (P<0.05,0.01).Fig. 1 CGA and Res mixed reagent are seen to inflammatory mediator in mice with acute lung injury BALF and are sticked point
The influence (n=8, M ± SD) of son, note：Compared with normal group,#P<0.05,##P<0.01；Compared with model group,*P<0.05,**P<
0.01；Compared with Res+CGA groups,ΔP<0.05,ΔΔP<0.01.Wherein, Figure 1A (A：The concentration of IL-6 in mouse BALF；B：Mouse
The concentration of TNF- in BALF)；Figure 1B (C：The concentration of P-selectin in mouse BALF；B：ICAM-1's is dense in mouse BALF
Degree)；
Influences of the 3.3Res+CGA to inflammatory mediator and adhesion molecule in ALI mice serums
Compared with normal group, the inflammatory mediator IL-6, TNF-α in model group mice serum and adhesion molecule P-
Selectin, ICAM-1 content dramatically increase (P<0.05,0.01).Compared with model group, CGA and Res+CGA groups can make small
IL-6, TNF-α and P-selectin, ICAM-1 content significantly reduce in mouse serum, and difference has statistical significance (P<
0.05,0.01), Res can be such that IL-6 and P-selectin, ICAM-1 content in mice serum significantly reduces, and difference has system
Meter learns meaning (P<0.05).Compared with Res+CGA groups, IL-6, TNF-α and P-selectin, ICAM-1 in Res group mice serums
Significantly higher (the P of content<0.05,0.01)；IL-6 and P-selectin contents are apparently higher than Res+CGA groups (P in CGA group serum<
0.05,0.01).See Fig. 2.Fig. 2 chlorogenic acids and resveratrol mixed reagent to inflammatory mediator in mice with acute lung injury serum and
The influence (n=8, M ± SD) of adhesion molecule, note：Compared with normal group,#P<0.05,##P<0.01；Compared with model group,*P<
0.05,**P<0.01；Compared with resveratrol+chlorogenic acid group,ΔP<0.05,ΔΔP<0.01.Wherein, Fig. 2A (A：In mice serum
The concentration of IL-6；B：The concentration of TNF- in mice serum)；Fig. 2 B (C：The concentration of P-selectin in mice serum；D：Mouse blood
The concentration of ICAM-1 in clear).
3.4 pathologic examination
Pathological section the results show that normally group lung tissue structure it is normal, rare inflammatory cell infiltration；Between the visible lung of model group
Matter is broadening, and alveolar is slightly expanded, universal visible inflammatory cell infiltration；The rare inflammatory cell infiltration of Res, CGA and Res+CGA group,
See Fig. 3 mouse lung tissues pathologic examination (× 200)；Wherein, A：Normal group；B：Model group；C：Resveratrol group；D：It is green
Ortho acid group；E resveratrols and chlorogenic acid drug combination group
Influences of the 3.5Res+CGA to ALI mouse NF- κ B p65 phosphorylation levels
Showed by immune group result, compared with normal group, the phosphorylation level of NF- κ B p65 in model group mouse lung tissue
Significantly increase (P<0.01)；CGA, Res and Res+CGA group can significantly reduce the phosphorylation level of NF- κ B p65 in lung tissue
(P<0.05,0.01).See Fig. 4：It is that chlorogenic acid and resveratrol are combined to NF- κ B p65 phosphorus in mice with acute lung injury lung tissue
It is acidified horizontal influence diagram (× 200) (n=8, M ± SD), Fig. 4 A are the immunohistochemistry testing result (× 200) of lung tissue
(A：Normal group；B：Model group；C：Resveratrol group；D：Chlorogenic acid group；E resveratrols and chlorogenic acid drug combination
Group)；Fig. 4 B are the analysis of NF- κ B p65 phosphorylation levels in lung tissue, wherein A：Normal group；B：Model group；C：Resveratrol
Group；D：Chlorogenic acid group；E：Resveratrol and chlorogenic acid drug combination group
Note：Compared with normal group, #P<0.05, ##P<0.01；Compared with model group, * P<0.05, * * P<0.01；With white lamb's-quarters
Reed alcohol+chlorogenic acid group compares,ΔP<0.05,ΔΔP<0.01。
4 discussion and conclusion
ALI be using inflammatory reaction and alveolar capillary inner film injury as major pathologic features, by inflammation medium and
A kind of common Severe acute disease of clinic that effector cell participates in jointly.The basic reason of ALI morbidities is the inflammatory that intrapulmonary is excessive, out of control
Reaction, complement play key player wherein[6].Complement is the important component of body immune system, the mistake of complement system
Degree activation, can stimulate neutrophil leucocyte and mononuclear phagocyte system, and by the activation of NF- κ B signal conduction paths, induction is big
The generation for measuring cell factor, inflammatory mediator and protease, causes the runaway inflammatory reaction of acute stage lung.
Res is a kind of polyphenol compound, is primarily present in the plants such as grape, peanut and giant knotweed, is ground to its mechanism
Study carefully relatively clear.Res can protect the small of many factors induction by the activation and oxidative stress for inhibiting NF- κ B signal accesses
Mouse ALI, meanwhile, we are in early-stage study it has also been found that Res is to human microvascular endothelial cell (mvec) inflammation caused by complement bypass-activation
Reaction has certain intervention effect.CGA also belongs to polyphenol compound, is many Chinese medicines such as honeysuckle, Honeysuckle flower, Cortex Eucommiae etc.
Typical reactive ingredient, have various biological activity.Our early-stage study finds CGA to people caused by complement bypass-activation
Microvascular endothelial cells inflammatory reaction has preferable intervention effect.Therefore, by our complements using seminar's structure early period
The ALI mouse models evaluation Res and CGA of road activation-inducing is combined intervention effect in vivo, observes it to the anti-inflammatory of ALI and protects
Shield acts on.
This experimental studies results shows that for continuous gavage after 1 week, CGA and Res combinations can substantially reduced mouse lung tissue inflammation
Infiltration, reduce neutrophil leucocyte intrapulmonary assemble, reduce BAL fluid in total number of cells, inflammatory mediator IL-6,
The concentration of proinflammatory factor IL-6 in TNF-α content and serum, TNF-α and adhesion molecule P-selectin, ICAM-1 mitigate NF- κ
B p65 phosphorylation levels, it is with obvious effects to be applied alone better than CGA or Res.The above result shows that CGA and Res combinations can effectively press down
The acute inflammatory phases of ALI early stages processed, the inflammation associated signal paths that mechanism may be mediated with inhibition NF- κ B p65 are to drop
Low inflammatory reaction is related.
The study show that CGA and Res combinations have preferably the acute inflammatory reaction of ALI caused by complement bypass-activation
Intervention effect.This research is not only that the further investigation for the pharmacological effect Function and its mechanisms for further excavating CGA, Res provides
Valuable thinking, while also reference frame is provided for the research and development and application of related new drug.
Experimental example 2
In acute lung injury, pyemia, ischemical reperfusion injury, burning (wound) wound, systemic inflammatory response syndrome, diabetes
Etc. in diseases, complement bypass-activation leads to that endothelial cell is inflamed reaction and damage is that above-mentioned many related diseases are levyd in disease
Important general character mechanism, in the experimental result of this case, composition of medicine can more effectively inhibit the mouse that complement bypass-activation induces
Acute lung injury, the index measured from lung's sample and Peripheral Blood sample clearly reflect that composition of medicine can more have
Effect inhibits the inflammatory reaction of vascular endothelial cell and the activation of inflammatory cell caused by complement bypass-activation, is based on above-mentioned other diseases
The general character pathologic basis at above-mentioned aspect with acute lung injury is levied, which can be equally used for the anti-of these related symptom
It controls.
The above description is merely a specific embodiment, but scope of protection of the present invention is not limited thereto, any
The change or replacement expected without creative work, should be covered by the protection scope of the present invention.Therefore, of the invention
Protection domain should be determined by the scope of protection defined in the claims.
Claims (5)
1. the inflammatory conditions protective agents based on blood vessel endothelium inflammatory damage, which is characterized in that the drug is active constituent
For the mixture of chlorogenic acid and resveratrol.
2. the inflammatory conditions protective agents according to claim 1 based on blood vessel endothelium inflammatory damage, which is characterized in that
The proportioning of the mixture is 4-6 parts of chlorogenic acid by weight, 1-3 parts of resveratrol.
3. the inflammatory conditions protective agents according to claim 2 based on blood vessel endothelium inflammatory damage, which is characterized in that
The proportioning of the mixture is 5 parts of chlorogenic acid by weight, 2 parts of resveratrol.
4. the inflammatory conditions protective agents according to claim 1 based on blood vessel endothelium inflammatory damage, which is characterized in that
The mixture is pill, tablet, injection or capsule.
5. according to the application of any inflammatory conditions protective agents based on blood vessel endothelium inflammatory damage of claim 1-3,
Specially：Application of the drug in terms of acute lung injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810330838.5A CN108478553A (en) | 2018-04-13 | 2018-04-13 | Based on the inflammatory conditions protective agents of blood vessel endothelium inflammatory damage and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810330838.5A CN108478553A (en) | 2018-04-13 | 2018-04-13 | Based on the inflammatory conditions protective agents of blood vessel endothelium inflammatory damage and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108478553A true CN108478553A (en) | 2018-09-04 |
Family
ID=63315763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810330838.5A Pending CN108478553A (en) | 2018-04-13 | 2018-04-13 | Based on the inflammatory conditions protective agents of blood vessel endothelium inflammatory damage and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108478553A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045279A (en) * | 2018-09-10 | 2018-12-21 | 因之彩生物科技（武汉）有限公司 | A kind of topical composition and its application and remedy for external use |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105902525A (en) * | 2016-04-21 | 2016-08-31 | 北京师范大学 | Application of chlorogenic acid nano powder inhalation in medicine for treating acute lung injury |
-
2018
- 2018-04-13 CN CN201810330838.5A patent/CN108478553A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105902525A (en) * | 2016-04-21 | 2016-08-31 | 北京师范大学 | Application of chlorogenic acid nano powder inhalation in medicine for treating acute lung injury |
Non-Patent Citations (3)
| Title |
|---|
| 周英 等: "绿原酸、咖啡酸和阿魏酸对补体旁路激活致内皮细胞炎症相关分子表达的干预", 《中国药理学通报》 * |
| 李朝胜 等: "三种化学小分子对补体旁路激活致内皮细胞黏附分子表达的干预及机制研究", 《中国药理学通报》 * |
| 陈向军 等: "白藜芦醇对脂多糖诱导的急性肺损伤的保护作用", 《中华肺部疾病杂志(电子版)》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045279A (en) * | 2018-09-10 | 2018-12-21 | 因之彩生物科技（武汉）有限公司 | A kind of topical composition and its application and remedy for external use |
| CN109045279B (en) * | 2018-09-10 | 2020-01-21 | 因之彩生物科技（武汉）有限公司 | External composition, application thereof and external therapeutic agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yin et al. | Roles of astrocytic connexin-43, hemichannels, and gap junctions in oxygen-glucose deprivation/reperfusion injury induced neuroinflammation and the possible regulatory mechanisms of salvianolic acid B and carbenoxolone | |
| Waterman et al. | Interstitial fluid and serum antibiotic concentrations | |
| CN100490891C (en) | Medicine composition for treating dysmenorrhea and its preparation process | |
| Wu et al. | Thrombopoietin could protect cerebral tissue against ischemia-reperfusion injury by suppressing NF-κB and MMP-9 expression in rats | |
| CN114588169A (en) | Application of fritillaria iso-steroid alkaloid monomer | |
| Lin et al. | Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway | |
| CN108635345A (en) | Based on the inflammatory conditions protective agents of blood vessel endothelium inflammatory damage and its application | |
| CN108478553A (en) | Based on the inflammatory conditions protective agents of blood vessel endothelium inflammatory damage and its application | |
| CN102526656B (en) | Medicament or health-care food composition for preventing or/and treating erythremia | |
| CN101095743B (en) | Exterior-applied medicine composition for treating gynecologic diseases and method of making the same and the use thereof | |
| Li et al. | Ginkgolide C attenuates cerebral ischemia/reperfusion-induced inflammatory impairments by suppressing CD40/NF-κB pathway | |
| Rathi et al. | Comparative evaluation of antipyretic activity of an ayurvedic herbo-mineral formulation dhatryadi churna and its modified dosage form in albino wistar rats | |
| CN1318439C (en) | Preparation method of amygdalin and its application in preparation of amygdalin preparation for promoting the blood circulation of heart, brain, pancreas and wound | |
| CN101926929A (en) | Traditional Chinese medicine for treating vascular dementia and preparation method thereof | |
| CN1504218A (en) | Medicine composition for tumour and its preparation method | |
| CN105056027B (en) | Effective part of glabrous greenbrier rhizome with red section and application thereof | |
| Ergon et al. | Evaluation of syringin? s neuroprotective effect in a model of neonatal hypoxic-ischemic brain injury | |
| CN113925869B (en) | Application of loratadine in preparing medicament for preventing and treating Vsig4 related diseases | |
| Karle | The site of abnormal erythrocyte destruction during experimental fever | |
| Vazirian et al. | Evaluation of the efficacy of Thymus kotschyanus extract as an additive treatment in patients with ulcerative colitis: a randomized double-blind placebo-controlled trial | |
| CN107669931A (en) | A kind of medicine for reducing furazolidone clinical treatment chronic enteritis side effect | |
| CN100486584C (en) | Application of amygdalin in preparation of amygdalin preparation for promoting the blood circulation of heart, brain, pancreas and wound | |
| Sun et al. | Effect of Xingnaojing injection on penumbra transformation in rats with acute cerebral ischemia. | |
| CN117942332A (en) | Application of carnosol in preparing medicament for treating or relieving cisplatin-induced acute kidney injury | |
| Abdillah et al. | Subacute Toxicity Test of Hydrocotyle Sibthorpioides Lam. Extract on Histopathological Images of Liver and Kidney of White Male Mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180904 |